These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 18939305)

  • 1. FDA notifications. Abacavir package insert changes approved. Hypersensitivity, other issues addressed.
    AIDS Alert; 2008 Sep; 23(9):102-4. PubMed ID: 18939305
    [No Abstract]   [Full Text] [Related]  

  • 2. Labeling changes for abacavir.
    AIDS Patient Care STDS; 2008 Aug; 22(8):683-4. PubMed ID: 18721055
    [No Abstract]   [Full Text] [Related]  

  • 3. FDA notifications. Ongoing safety review of abacavir, possible MI risk.
    AIDS Alert; 2011 May; 26(5):58-9. PubMed ID: 21649950
    [No Abstract]   [Full Text] [Related]  

  • 4. FDA notifications. Large study suggests heart attack risk from use of abacavir or didanosine.
    AIDS Alert; 2008 May; 23(5):58-9. PubMed ID: 18642404
    [No Abstract]   [Full Text] [Related]  

  • 5. Abacavir warning.
    AIDS Patient Care STDS; 2000 Nov; 14(11):617. PubMed ID: 11155904
    [No Abstract]   [Full Text] [Related]  

  • 6. 1592 (abacavir): do not rechallenge after hypersensitivity reaction.
    James JS
    AIDS Treat News; 1997 Dec; (No 285):1, 5. PubMed ID: 11364916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FDA notifications. Abacavir sulfate tablets tentatively approved.
    AIDS Alert; 2011 May; 26(5):59-60. PubMed ID: 21648134
    [No Abstract]   [Full Text] [Related]  

  • 8. Understanding drug hypersensitivity: what to look for when prescribing abacavir.
    Hetherington S
    AIDS Read; 2001 Dec; 11(12):620-2. PubMed ID: 11806176
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA notifications. FDA changes information for stavudine label.
    AIDS Alert; 2002 May; 17(5):67. PubMed ID: 12030220
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA notifications. Abacavir approved for pediatric patients.
    AIDS Alert; 2009 Feb; 24(2):21-2. PubMed ID: 19222148
    [No Abstract]   [Full Text] [Related]  

  • 11. FDA notifications. Abacavir tablet approved for pediatric patients.
    AIDS Alert; 2008 Nov; 23(11):128-9. PubMed ID: 19048648
    [No Abstract]   [Full Text] [Related]  

  • 12. Genetic testing may avoid abacavir hypersensitivity reaction.
    James JS
    AIDS Treat News; 2006; (419):6-7. PubMed ID: 17096489
    [TBL] [Abstract][Full Text] [Related]  

  • 13. FDA notifications. FDA approves generic abacavir.
    AIDS Alert; 2010 Nov; 25(11):130-1. PubMed ID: 21132857
    [No Abstract]   [Full Text] [Related]  

  • 14. Severe hypersensitivity reactions following reintroduction of abacavir.
    AIDS Read; 2000 Sep; 10(9):525. PubMed ID: 11019447
    [No Abstract]   [Full Text] [Related]  

  • 15. FDA notifications. Generic abacavir and lamivudine combo approved.
    AIDS Alert; 2008 Oct; 23(10):115. PubMed ID: 18935685
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial comment: the challenge of prescribing abacavir.
    Ball SC
    AIDS Read; 2001 Dec; 11(12):621. PubMed ID: 11806177
    [No Abstract]   [Full Text] [Related]  

  • 17. Abacavir hypersensitivity.
    Vandekerckhove L; Blot S; Vogelaers D
    N Engl J Med; 2008 Jun; 358(23):2514-5; author reply 2515-6. PubMed ID: 18525052
    [No Abstract]   [Full Text] [Related]  

  • 18. Abacavir hypersensitivity reaction predicted by genetic test.
    AIDS Treat News; 2004 Mar; (399):6. PubMed ID: 15199868
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-HIV agents. Who gets abacavir allergies?
    TreatmentUpdate; 2003 Oct; 15(6):4-5. PubMed ID: 17219615
    [No Abstract]   [Full Text] [Related]  

  • 20. Complications and side effects. Abacavir hypersensitivity testing results--Montreal.
    TreatmentUpdate; 2007; 19(5):8-9. PubMed ID: 17955617
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.